Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Italy Fines Apple €98.6 Million Over App Store Dominance 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
NEW YORK, Feb. 12, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Nobilis Health Corp. (“Nobilis”) (NYSE MKT:HLTH) between April 2, 2015 and January 6, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of Texas on behalf of Nobilis shareholders. If you purchased or otherwise acquired Nobilis securities between April 2, 2015 and January 6, 2016, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/nobilis-health
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued materially false and misleading statements to investors and/or failed to disclose that: (1) Nobilis’ financial statements contained numerous errors concerning the classification of warrants and options, business combination accounting, share-based compensation, and other financial and operating results; (2) Nobilis overstated its net income for the year ended December 31, 2014 by more than $4 million; (3) Nobilis overstated its net income for the quarter ended March 31, 2015 by more than $3.27 million; and (4) as a result, defendants’ statements about Nobilis’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Nobilis you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
